Search

Ophthalmic Aid to Eastern Europe (OAEE)

Peter Cackett, Tim ffytche and Dr Irina Gout reflect on historic ophthalmic aid sent to Eastern Europe. This article was written prior to the horrific events in Ukraine. An appeal for funds and equipment may be made by OAEE later...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

A three-way partnership between Nigeria, Tanzania and Northern Ireland

VISION 2020 LINKS between Western Health and Social Care Trust (WHSCT), Altnagelvin Area Hospital, Northern Ireland with first ECWA Eye Hospital, Kano, Nigeria and now also with Mbeya Referral Hospital (MRH), Tanzania, have been beneficial to all three partners. From...

Sickle cell eye disease: an overview of vitreoretinal complications and their surgical management

Sickle cell disease is the most common genetic disorder worldwide and is associated with lifelong anaemia, intermittent pain and multi-organ morbidity. Ocular involvement can be associated with significant visual impairment due to the complications of proliferative sickle retinopathy (PSR). Occasionally...

What’s new in wet AMD papers?

Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...

The David J Apple International Laboratory for Ocular Pathology – a legacy of pioneering IOL research

David Apple and Gerd Auffarth. The Apple Lab at the David J Apple Center for Vision Research in Heidelberg is a thriving international laboratory for research into intraocular devices. The lab continues the work of David J Apple, a world-renowned...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...

Can 3D facial imaging improve patient management in disfiguring eye disease?

Fight for Sight is the leading UK charity funder of eye research. Since the 2013 Sight Loss and Vision Priority Setting Partnership we have encouraged our researchers to work on priorities jointly identified by people affected by sight loss and...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...

Patient and public participation shapes biomedical research and access priorities in eye health

Patients, clinicians and clinician-scientists play a valuable role in shaping the future of vision research. Limited funding demands targeted research initiatives that ultimately will shape health policy and practice to secure progress in improving patient outcomes in eye health. This...

COVID-19: Pete’s Bogus Journey

The author shares his personal experience of contracting coronavirus. I managed to body swerve COVID-19 for nine months. The Pfizer vaccine was being rolled out in my trust. I had my first inoculation booked in three weeks. I had survived...